Stocks · News reference

Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

Aug 7, 2026, 5:00 PMBenzinga Newsdesk

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $55.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 7, 2026, 5:00 PM
Checked: Aug 7, 2026, 5:00 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 24, 2026, 5:28 PMBenzinga Newsdesk
Janux Therapeutics shares are trading higher after Wolfe Research upgraded the stock from Peer Perform to Outperform rating and announced a $23 price target.
Read original at benzinga
JANX
BenzingaAug 24, 2026, 3:44 PMAvi Kapoor
This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list. DRI, JANX, and more mentioned.
Read original at benzinga
AEVA CLS DRI JANX MT
BenzingaAug 24, 2026, 12:17 PMBenzinga Newsdesk
Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target
Read original at benzinga
JANX